Thyroid dysfunction in MASLD: Results of a nationwide study

The approval by the US FDA of resmetirom, a thyroid hormone receptor β-selective agonist for non-cirrhotic metabolic dysfunction-associated steatohepatitis with stage 2-3 fibrosis, highlights the potential role of thyroid dysfunction in metabolic-associated steatotic liver disease (MASLD). This study identified hypothyroidism as a risk factor for MASLD, especially in men and individuals younger than 40 years, with the association peaking at non-cirrhotic fibrosis. Metabolic disorders mediated ∼41% of the hypothyroidism-MASLD association. Hyperthyroidism was potentially inversely associated with MASLD. Despite its low prevalence (2.5% in MASLD cases, 1.4% in controls), the population health impact of hypothyroidism warrants further attention.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-02-26
DOI
https://doi.org/10.1016/j.jhepr.2025.101369
Citations
2
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
3.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Thyroid dysfunction in MASLD: Results of a nationwide study

Marijana Vujković, Eleonora Scorletti, Jie Chen, David Bergman et al.
2 citations
JHEP Reports
Genetic Associations and Epidemiology
3.63
article

Thyroid dysfunction in MASLD: Results of a nationwide study

Marijana Vujković, Eleonora Scorletti, Jie Chen, David Bergman, Hannes Hagström, Fahim Ebrahimi, Jonas Filip Ludvigsson, Shuai Yuan, Xiangyan Ruan
article en
2 citations

Abstract

The approval by the US FDA of resmetirom, a thyroid hormone receptor β-selective agonist for non-cirrhotic metabolic dysfunction-associated steatohepatitis with stage 2-3 fibrosis, highlights the potential role of thyroid dysfunction in metabolic-associated steatotic liver disease (MASLD). This study identified hypothyroidism as a risk factor for MASLD, especially in men and individuals younger than 40 years, with the association peaking at non-cirrhotic fibrosis. Metabolic disorders mediated ∼41% of the hypothyroidism-MASLD association. Hyperthyroidism was potentially inversely associated with MASLD. Despite its low prevalence (2.5% in MASLD cases, 1.4% in controls), the population health impact of hypothyroidism warrants further attention.

JHEP ReportsVol. 7(5)
National Health Service (GB), Karolinska University Hospital (SE), Central South University (CN), Columbia University Irving Medical Center (US), University Hospital of Basel (CH), University Hospital Southampton NHS Foundation Trust (GB), Karolinska Institutet (SE), National Institute for Health and Care Research (GB), Örebro University Hospital (SE), Philadelphia VA Medical Center (US), Third Xiangya Hospital (CN), University of Southampton (GB), University of Pennsylvania (US)
American Heart Association
Zero hunger
Openalex Percentile: Top 9%
Genetic Associations and Epidemiology
3.63
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.